178 related articles for article (PubMed ID: 18334100)
1. Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking.
Skopp G; Pötsch L
J Anal Toxicol; 2008 Mar; 32(2):160-4. PubMed ID: 18334100
[TBL] [Abstract][Full Text] [Related]
2. [Serum cannabinoid levels 24 to 48 hours after cannabis smoking].
Skopp G; Richter B; Pötsch L
Arch Kriminol; 2003; 212(3-4):83-95. PubMed ID: 14639811
[TBL] [Abstract][Full Text] [Related]
3. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.
Fabritius M; Chtioui H; Battistella G; Annoni JM; Dao K; Favrat B; Fornari E; Lauer E; Maeder P; Giroud C
Anal Bioanal Chem; 2013 Dec; 405(30):9791-803. PubMed ID: 24202191
[TBL] [Abstract][Full Text] [Related]
5. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.
Desrosiers NA; Himes SK; Scheidweiler KB; Concheiro-Guisan M; Gorelick DA; Huestis MA
Clin Chem; 2014 Apr; 60(4):631-43. PubMed ID: 24563491
[TBL] [Abstract][Full Text] [Related]
6. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
[TBL] [Abstract][Full Text] [Related]
7. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana.
Huestis MA; Henningfield JE; Cone EJ
J Anal Toxicol; 1992; 16(5):276-82. PubMed ID: 1338215
[TBL] [Abstract][Full Text] [Related]
8. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.
Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
J Anal Toxicol; 2019 May; 43(4):233-258. PubMed ID: 30615181
[TBL] [Abstract][Full Text] [Related]
9. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid concentrations in hair from documented cannabis users.
Huestis MA; Gustafson RA; Moolchan ET; Barnes A; Bourland JA; Sweeney SA; Hayes EF; Carpenter PM; Smith ML
Forensic Sci Int; 2007 Jul; 169(2-3):129-36. PubMed ID: 16963215
[TBL] [Abstract][Full Text] [Related]
11. Detection of in utero cannabis exposure by umbilical cord analysis.
Kim J; de Castro A; Lendoiro E; Cruz-Landeira A; López-Rivadulla M; Concheiro M
Drug Test Anal; 2018 Apr; 10(4):636-643. PubMed ID: 28948698
[TBL] [Abstract][Full Text] [Related]
12. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.
Karschner EL; Schwilke EW; Lowe RH; Darwin WD; Herning RI; Cadet JL; Huestis MA
J Anal Toxicol; 2009 Oct; 33(8):469-77. PubMed ID: 19874654
[TBL] [Abstract][Full Text] [Related]
13. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations.
Huestis MA; Barnes A; Smith ML
Clin Chem; 2005 Dec; 51(12):2289-95. PubMed ID: 16223887
[TBL] [Abstract][Full Text] [Related]
14. Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).
Holland MG; Schwope DM; Stoppacher R; Gillen SB; Huestis MA
Forensic Sci Int; 2011 Oct; 212(1-3):247-51. PubMed ID: 21764230
[TBL] [Abstract][Full Text] [Related]
15. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.
Scheidweiler KB; Schwope DM; Karschner EL; Desrosiers NA; Gorelick DA; Huestis MA
Clin Chem; 2013 Jul; 59(7):1108-17. PubMed ID: 23519966
[TBL] [Abstract][Full Text] [Related]
16. [Time profile of serum THC levels in occasional and chronic marihuana smokers after acute drog use - implication for drivind motor vehicles].
Balíková M; Hložek T; Páleníček T; Tylš F; Viktorinová M; Melicher T; Androvičová R; Tomíček P; Roman M; Horáček J
Soud Lek; 2014; 59(1):2-6. PubMed ID: 24625019
[TBL] [Abstract][Full Text] [Related]
17. Assessing cannabis consumption frequency: Is the combined use of free and glucuronidated THCCOOH blood levels of diagnostic utility?
Hädener M; Martin Fabritius M; König S; Giroud C; Weinmann W
Drug Test Anal; 2017 Jul; 9(7):1043-1051. PubMed ID: 27732768
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of postmortem concentrations of Δ
Hoffman MA; Trochta A; Gary RD; Fitzgerald RL; McIntyre IM
Forensic Sci Int; 2020 Oct; 315():110414. PubMed ID: 32738674
[TBL] [Abstract][Full Text] [Related]
19. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.
Karschner EL; Schwope DM; Schwilke EW; Goodwin RS; Kelly DL; Gorelick DA; Huestis MA
Drug Alcohol Depend; 2012 Oct; 125(3):313-9. PubMed ID: 22464363
[TBL] [Abstract][Full Text] [Related]
20. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?
Karschner EL; Schwilke EW; Lowe RH; Darwin WD; Pope HG; Herning R; Cadet JL; Huestis MA
Addiction; 2009 Dec; 104(12):2041-8. PubMed ID: 19804462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
